{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:56:09Z","timestamp":1794938169989,"version":"4.9.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Japanese Ministry of Health, Labour and Welfare"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine whether early therapeutic intervention, compared with delayed intervention, is beneficial for patients with early SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a single-centre, retrospective cohort study of SSc patients who received CYC, MMF, MTX or tocilizumab for diffuse cutaneous SSc (dcSSc) or interstitial lung disease (ILD) within 6\u2009years after disease onset. The patients were divided into early and delayed intervention groups based on the disease duration of \u226418 and &amp;gt;18\u2009months at treatment introduction, respectively. Clinical worsening was defined as the development of any original or revised ACR Composite Response Index in SSc (CRISS) step 1 event or progressive fibrosing ILD (PF-ILD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was no difference in baseline characteristics between the early (n\u2009=\u200925) and delayed (n\u2009=\u200921) intervention groups except forced vital capacity, which was better in the early vs delayed intervention groups. The early intervention group less frequently had stable pulmonary function over 1\u2009year than did the late intervention group (odds ratio 0.087, 95% CI: 0.0079, 0.51; P\u2009=\u20090.003). The active disease was significantly decreased from 79% to 42% in the early intervention group (P\u2009=\u20090.007), but the change in the delayed intervention group was not statistically significant (68% to 42%; P\u2009=\u20090.11). Cumulative rates free from clinical worsening events defined by revised ACR-CRISS and PF-ILD were significantly higher in the early vs delayed intervention groups (P\u2009=\u20090.03 and 0.003, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A therapeutic \u2018window of opportunity\u2019 might exist in SSc patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab931","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T12:33:23Z","timestamp":1639571603000},"page":"3677-3685","source":"Crossref","is-referenced-by-count":19,"title":["Outcomes in patients with systemic sclerosis undergoing early <i>vs<\/i> delayed intervention with potential disease-modifying therapies"],"prefix":"10.1093","volume":"61","author":[{"given":"Keina","family":"Yomono","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine"},{"name":"Scleroderma\/Myositis Center of Excellence, Nippon Medical School Hospital , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"2022090108150251700_keab931-B1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2022090108150251700_keab931-B2","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022090108150251700_keab931-B3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/art.41246","article-title":"Current and future outlook on disease modification and defining low disease activity in systemic sclerosis","volume":"72","author":"Nagaraja","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022090108150251700_keab931-B4","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2022090108150251700_keab931-B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"2022090108150251700_keab931-B6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B7","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","author":"Lescoat","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022090108150251700_keab931-B8","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2022090108150251700_keab931-B9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2022090108150251700_keab931-B10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2022090108150251700_keab931-B11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"van Nies","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B13","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2022090108150251700_keab931-B14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","article-title":"Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database","volume":"75","author":"Wirz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B16","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"2022090108150251700_keab931-B17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2022090108150251700_keab931-B18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthrtis Rheumatol"},{"key":"2022090108150251700_keab931-B19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.55563\/clinexprheumatol\/i80zh7","article-title":"A randomized, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale","volume":"39","author":"Spiera","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2022090108150251700_keab931-B20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2022090108150251700_keab931-B21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B22","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3899\/jrheum.151440","article-title":"Summed and weighted summary scores for the Medsger disease severity scale compared with the physician's global assessment of disease severity in systemic sclerosis","volume":"43","author":"Harel","year":"2016","journal-title":"J Rheumatol"},{"key":"2022090108150251700_keab931-B23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J Nippon Med Sch"},{"key":"2022090108150251700_keab931-B24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal clinically important differences for the modified Rodnan skin score: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022090108150251700_keab931-B25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/14397595.2020.1784548","article-title":"Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: results from a multicentre prospective cohort in Japan","volume":"31","author":"Kuwana","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2022090108150251700_keab931-B26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD) \u2013 report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"2022090108150251700_keab931-B27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022090108150251700_keab931-B28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2022090108150251700_keab931-B30","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00296-019-04357-x","article-title":"Targeting very early systemic sclerosis: a case-based review","volume":"39","author":"Melissaropoulos","year":"2019","journal-title":"Rheumatol Int"},{"key":"2022090108150251700_keab931-B31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: Results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022090108150251700_keab931-B32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022090108150251700_keab931-B33","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/rheumatology\/kez407","article-title":"Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis","volume":"59","author":"Hoa","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022090108150251700_keab931-B34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2022090108150251700_keab931-B35","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2022090108150251700_keab931-B36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3899\/jrheum.180582","article-title":"Scleroderma renal crisis: Risk factors for an increasingly rare organ complication","volume":"47","author":"Moinzadeh","year":"2020","journal-title":"J Rheumatol"},{"key":"2022090108150251700_keab931-B37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022090108150251700_keab931-B38","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1136\/annrheumdis-2021-220402","article-title":"Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis","volume":"80","author":"Clark","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab931\/42073409\/keab931.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/9\/3677\/45626865\/keab931.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/9\/3677\/45626865\/keab931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T08:37:27Z","timestamp":1662021447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/9\/3677\/6468620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,12,17]]},"published-print":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab931","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2021,12,17]]}}}